Quarterly report pursuant to Section 13 or 15(d)

License and Collaboration Agreements, Viatris License Agreement (Details)

v3.24.1.1.u2
License and Collaboration Agreements, Viatris License Agreement (Details)
 1 Months Ended 3 Months Ended
Nov. 06, 2022
USD ($)
Nov. 30, 2022
USD ($)
Mar. 31, 2024
USD ($)
Performanceobligation
Mar. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
Collaboration and License Agreement [Abstract]          
Revenue recognized     $ 1,711,000 $ 1,749,000  
Reconciliation of Closing Balance of Contract Asset [Abstract]          
Revenue recognized     $ 1,711,000 1,749,000  
Viatris License Agreement [Member]          
Collaboration and License Agreement [Abstract]          
Non-refundable cash payment received   $ 35,000,000      
Maximum amount of payments receivable for development, regulatory and commercial milestones $ 130,000,000        
Milestone payments to be received 10,000,000        
Maximum percentage of tiered royalties receivable     20.00%    
Number of distinct performance obligations | Performanceobligation     2    
Aggregate transaction price to be recognized     $ 40,000,000    
Period of non-cancellation window agreement     120 days    
Non-cancellation period of constrained     120 days    
Royalty payments     $ 3,000    
Revenue recognized     1,711,000 1,749,000  
Reconciliation of Closing Balance of Contract Asset [Abstract]          
Beginning Balance     1,407,000 3,552,000  
Revenue recognized     1,711,000 1,749,000  
Ending Balance     1,194,000 2,467,000  
Viatris License Agreement [Member] | License Transfer Fee [Member]          
Collaboration and License Agreement [Abstract]          
Aggregate transaction price to be recognized     35,000,000    
Estimated standalone selling price for license agreement 287,800,000        
Transaction price allocation of ESSP obligations 39,300,000        
Reconciliation of Closing Balance of Contract Asset [Abstract]          
Reclassification to accounts receivable related to costs billed under the Viatris License Agreement     (1,924,000) $ (2,834,000)  
Viatris License Agreement [Member] | Research and Development Services [Member]          
Collaboration and License Agreement [Abstract]          
Aggregate transaction price to be recognized     5,000,000    
Estimated standalone selling price for license agreement 5,000,000        
Transaction price allocation of ESSP obligations $ 700,000        
Viatris License Agreement [Member] | Sales Milestones [Member]          
Collaboration and License Agreement [Abstract]          
Milestone payment requirements attributed to the FDA's approval         $ 10,000,000
Revenue recognized     0    
Reconciliation of Closing Balance of Contract Asset [Abstract]          
Revenue recognized     $ 0